Toward Better Understanding and Management of Solitary Fibrous Tumor

Surg Oncol Clin N Am. 2022 Jul;31(3):459-483. doi: 10.1016/j.soc.2022.03.009.

Abstract

Solitary fibrous tumor (SFT) comprises a histologic spectrum of soft tissue neoplasms that are characterized by the unique NAB2-STAT6 gene fusion. Changes in diagnostic terminology and site-specific classification over the past few decades have resulted in a disjointed literature. Complete surgical excision with preservation of function remains the mainstay of treatment. New risk stratification systems including risk factors such as mitotic rate, age, tumor size, and presence of necrosis, among others, can be used to predict risk of recurrence or metastasis. Long-term follow-up after surgical resection is recommended. The clinical manifestations, diagnosis, management, and prognosis of SFT are reviewed here.

Keywords: NAB2-STAT6; Prognostic factors; Risk stratification; Solitary fibrous tumor; Surgery; Survival; Therapeutic strategies.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / genetics
  • Gene Fusion
  • Humans
  • Prognosis
  • Repressor Proteins / genetics
  • Soft Tissue Neoplasms*
  • Solitary Fibrous Tumors* / diagnosis
  • Solitary Fibrous Tumors* / genetics
  • Solitary Fibrous Tumors* / surgery

Substances

  • Biomarkers, Tumor
  • Repressor Proteins